Journal
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
Volume 1870, Issue 1, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.bbadis.2023.166881
Keywords
Gastric cancer; PD-1/PD-L1; Immune checkpoint inhibitors; Immunotherapy
Ask authors/readers for more resources
Gastric cancer is a global health problem, and traditional therapies have limited efficacy. Immunotherapy using checkpoint inhibitors, particularly therapeutic antibodies targeting the PD-1/PD-L1 pathway, has made substantial breakthroughs in the treatment of gastric cancer.
Gastric cancer (GC) is an increasing global health problem and is one of the leading cancers worldwide. Traditional therapies, such as radiation and chemotherapy, have made limited progress in enhancing their efficacy for advanced GC. The development of immunotherapy for advanced GC has considerably improved with a deeper understanding of the tumor microenvironment. Immunotherapy using checkpoint inhibitors is a new therapeutic option that has made substantial advances in the treatment of other malignancies and is increasingly used in other clinical oncology treatments. Particularly, therapeutic antibodies targeting the programmed cell death protein-1 (PD-1)/programmed cell death ligand 1 (PD-L1) pathway have been effectively used in the clinical treatment of cancer. Monoclonal antibodies blocking the PD-1/PD-L1 pathway have been developed for cancer immunotherapy to enhance T cell function to restore the immune response and represent a breakthrough in the treatment of GC. This review provides an outline of the progress of PD-1/PD-L1 blockade therapy and its expression characteristics and clinical application in advanced GC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available